CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Pascal Soriot

Chief Executive Officer & Executive Director, AstraZeneca

Search every verified Pascal Soriot interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. During AstraZeneca's Q2 2026 earnings call on July 27, 2026, Pascal Soriot addressed the company's growth outlook and pipeline strategy. He stated that AstraZeneca does not require additional business development to achieve its 2030 growth targets, while noting that this assumption depends on the aggregate probability of success across its pipeline of new products. Soriot also highlighted three recent launches with peak revenue potential exceeding $5 billion each, and described a broader portfolio of assets expected to deliver pivotal data before 2030, including programs with multi-blockbuster potential. On the call, Soriot also discussed opportunities in gastric cancer, referencing a study expansion for a therapy with a Claudin 18.2 positivity cutoff greater than 25%, which he said represents about half of patients with gastric or gastroesophageal junction cancer. He mentioned plans to combine the therapy with immuno-oncology agents in a first-line setting. Regarding a legal matter, Soriot noted that AstraZeneca had initiated an arbitration process in the United States and declined to comment further on the proceedings. He reaffirmed that the company remains on track for its 2030 goals and its post-2030 ambitions.

Recent appearances

Notable quotes

“This investment will help us realize our ambition to reach our 80 billion target by 2030. But the dollar number is an important one of course because you need turnover, you need profitability to be able to reinvest in R&D and we invest about 14 billion dollars in R&D today.”

“We have 23 sites in the US. We have a workforce of about 25,000 people around the country. And this $50 billion will help us continue to increase our footprint not only in manufacturing but also in R&D.”

“Innovation in our industry is led out of this country and we need to make sure that everything is done to keep the lead that this country has in bioharmaceutical innovation around the world because the competition is fierce. China is ramping up. Unfortunately, US is kind of alone. Europe is falling back. But certainly competition with China is very fierce.”

“We decided to do this because we wanted to become more American for sure and allow American investors to access our shares more directly than NDR. But we also wanted to align our shares across the United States, New York, but also London and Stockholm in Sweden. So that we have a harmonized global listing across the world.”

“A merger would totally distract us; I didn't think it would create value and I thought we could do well or better on our own.”

“We had to sell all products, take the profit and put it into R&D — there was no guarantee of success in the R&D investments; if R&D had not delivered we were finished.”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →